EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Gene Expression Signatures Predict First-Year Response to Somapacitan Treatment in Children With Growth Hormone Deficiency

Terence Garner, Peter Clayton iD, Michael Højby, Philip Murray, Adam Stevens iD

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgad717 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Terence Garner und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Developmental Biology and Medicine, Faculty of Biology, Medicine and Health, University of Manchester and Manchester Academic Health Scie…. Hauptthemen laut MEDLINE: Dwarfism, Pituitary, Histidine, Human Growth Hormone, Mannitol. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

The pretreatment blood transcriptome predicts growth response to daily growth hormone (GH) therapy with high accuracy.

Objective

Investigate response prediction using pretreatment transcriptome in children with GH deficiency (GHD) treated with once-weekly somapacitan, a novel long-acting GH.

Methods

REAL4 is a randomized, multinational, open-label, active-controlled parallel group phase 3 trial, comprising a 52-week main phase and an ongoing 3-year safety extension (NCT03811535). A total of 128/200 treatment-naïve prepubertal children with GHD consented to baseline blood transcriptome profiling. They were randomized 2:1 to subcutaneous somapacitan (0.16 mg/kg/week) or daily GH (0.034 mg/kg/day). Differential RNA-seq analysis and machine learning were used to predict therapy response.

Results

121/128 samples passed quality control. Children treated with somapacitan (n = 76) or daily GH (n = 45) were categorized based on fastest and slowest growing quartiles at week 52. Prediction of height velocity (HV; cm/year) was excellent for both treatments (out of bag [OOB] area under curve [AUC]: 0.98-0.99; validation AUC: 0.83-0.84), as was prediction of secondary markers of growth response: HV standard deviation score (SDS) (0.99-1.0; 0.75-0.78), change from baseline height SDS (ΔHSDS) (0.98-1.0; 0.61-0.75), and change from baseline insulin-like growth factor-I SDS (ΔIGF-I SDS) (0.96-1.0; 0.85-0.88). Genes previously identified as predictive of GH therapy response were consistently better at predicting the fastest growers in both treatments in this study (OOB AUC: 0.93-0.97) than the slowest (0.67-0.85).

Conclusion

Pretreatment transcriptome predicts first-year growth response in somapacitan-treated children with GHD. A common set of genes can predict the treatment response to both once-weekly somapacitan and conventional daily GH. This approach could potentially be developed into a clinically applicable pretreatment test to improve clinical management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dwarfism, PituitaryHistidineHuman Growth HormoneMannitolPhenolChildHumansBody HeightGrowth HormoneInsulin-Like Growth Factor ITranscriptome

Stichwörter der Autor:innen

and RNA sequencinggrowth hormone deficiencylong-acting growth hormonepredictive markerspretreatment blood transcriptomesomapacitan

Substanzen

Growth HormoneHistidineHuman Growth HormoneInsulin-Like Growth Factor IMannitolPhenolsomapacitan

Autor:innen und Institutionen

  • Division of Developmental Biology and Medicine, Faculty of Biology, Medicine and Health, University of Manchester and Manchester Academic Health Science Centre, Manchester, M13 9WL, UK.
  • Department of Paediatric Endocrinology, Royal Manchester Children's Hospital, Manchester, M13 9WL, UK.
  • Novo Nordisk, Clinical Drug Development, 2860 Søborg, Denmark.

ORCID-Profile: Peter Clayton, Adam Stevens

Förderung

  • Novo Nordisk A/S

Zitieren

APA

Garner, T., Clayton, P., Højby, M., Murray, P., & Stevens, A. (2024). Gene Expression Signatures Predict First-Year Response to Somapacitan Treatment in Children With Growth Hormone Deficiency. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad717

Vancouver

Garner T, Clayton P, Højby M, Murray P, Stevens A. Gene Expression Signatures Predict First-Year Response to Somapacitan Treatment in Children With Growth Hormone Deficiency. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad717

BibTeX
@article{Garner2024,
  author = {Garner, Terence and Clayton, Peter and Højby, Michael and Murray, Philip and Stevens, Adam},
  title = {Gene Expression Signatures Predict First-Year Response to Somapacitan Treatment in Children With Growth Hormone Deficiency},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgad717}
}
Kostenlos starten →